Abstract
Our series of five cases enabled a direct comparison of the pharmacokinetic (PK) profiles of turoctocog alfa pegol versus efmoroctocog alfa, a recombinant a factor VIII‐Fc fusion protein, performed in the same subjects with severe hemophilia A within a short time-frame. Half-life values were significantly longer, by about 1 hour, with turoctocog alfa pegol than with efmoroctocog alfa. The estimated time spent with FVIII levels above 5% when infusing every 4 days was significantly longer with turoctocog alfa pegol. When feasible, the possibility of executing a PK curve should be considered, in order to use the parameters obtained as the main indicators and predictors of coagulation support.
References
Downloads
pdf
Authors
Alessandra Poz
University Hospital of Udine, Udine, Italy
Laura Contino Azienda Ospedaliera "SS Antonio e Biagio", Alessandria, Italy
Giovanni Barillari
University Hospital of Udine, Udine, Italy
- Abstract viewed - 838 times
- pdf downloaded - 0 times